Mr. Cohen joined our Board of Directors in 2023. Since 2020, he has been Chairman of the Board of Directors and Chief Executive Officer of Quark Pharmaceuticals, Inc. Mr. Cohen also serves on the Boards of Directors of Ayana Pharma Ltd. and Silver Castle Holdings Ltd (TASE: SLCL). From November 2006 to May 2019, Mr. Cohen served as President and Chief Executive Officer of MediWound Ltd., leading the development of their innovative biological drug for burn treatment up to marketing authorization and commercialization in numerous international markets, as well as their initial public offering on Nasdaq. Prior to that, from 2004 to 2006, Mr. Cohen served as Director of Strategic Business Planning and New Ventures at Teva Pharmaceuticals Ltd. From 2000 to 2004, Mr. Cohen served at Teva’s Global Products Division as Project Manager for the launch of Copaxone® in Europe and numerous other countries, and from 1998 to 2000, he led projects at Teva’s Corporate Industrial Engineering Department. Mr. Cohen holds a B.Sc. in Industrial Engineering and Management (cum laude) from the Technion-Israel Institute of Technology and an M.B.A. (cum laude) from Tel Aviv University.